In response to a patient inquiry, Dr. Richard LaFountain provides an overview of the current evidence surrounding methylene blue dosing protocols for the adjunctive treatment of depression. The article summarizes key findings from clinical trials suggesting that lower doses of methylene blue—once considered sub-therapeutic—may yield comparable benefits to higher doses while reducing the likelihood of adverse effects.